MLN8237 (alisertib)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for MLN8237 (alisertib), covering 2016-05-25 to 2018-05-17. Get the full timeline:
Most recent: Clinical Trial Update: Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer [Phase 1, Phase 2]